20 min.
In dit journaal bespreek prof. dr. Josée Zijlstra haar persoonlijke selectie van het ASH-nieuws over Hodgkin lymfomen.
Directe links naar de abstracts:
1. Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
2. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
3. Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical